Millie Ray

Partner at The Column Group

Dr. Ray joined The Column Group in 2017. Previously, Dr. Ray was an Associate of Business Development at Foghorn Therapeutics, which she helped launch with Flagship Pioneering. Dr. Ray helped develop and execute the scientific, business and operating plans for Foghorn Therapeutics. Dr. Ray helped establish the first onsite next-generation sequencers for Ebola viral surveillance with Dr. Pardis Sabeti’s lab at Harvard University and the Broad Institute. Previously, Dr. Ray completed her PhD at Harvard University with Dr. Robert Kingston, studying the effects of long non-coding RNAs on epigenetic regulation. Dr. Ray holds undergraduate degrees in Biology and Mathematics from the Massachusetts Institute of Technology, where she also performed embryonic stem cell research in the lab of Dr. Rudolf Jaenisch.

Links

Previous companies


Org chart

No direct reports

Teams


Offices

This person is not in any offices


The Column Group

1 followers

The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early-stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics.


Industries

Employees

11-50

Links